Navigation Links
Blood-Thinner No Help for Dialysis Treatment
Date:5/13/2008

Plavix didn't improve results for patients who underwent circulatory procedure

TUESDAY, May 13 (HealthDay News) -- A major trial has dashed the hope that the clot-preventing drug Plavix could help in the delicate balancing act needed to establish a blood vessel suitable for dialysis for kidney patients.

Giving Plavix (clopidogrel) did reduce the risk that a blood clot would block the vessel created by combining a vein and an artery, a standard procedure for kidney dialysis. But adding the clot-preventing drug did not increase the number of fistulas, as they are called, that could be used for artificial kidney treatment over the long run, the study authors reported.

The study was done because "early thrombosis [blood clotting] is one of the major causes of fistula failure," said Dr. Laura M. Dember, an associate professor of medicine at Boston University, and lead author of the report.

"What we found was that despite the reduction in thrombosis that was clear enough, there was an equal proportion of fistula failure," Dember said. "What is ultimately important is the usability of the fistula for dialysis."

The researchers published their findings in the May 14 issue of the Journal of the American Medical Association.

About 470,000 Americans have kidney failure and are kept alive by dialysis, in which their blood is run through a machine that filters out impurities. The preferred technique for linking to the artificial kidney is to create a fistula, which has lower rates of thrombosis -- blockage -- and infection than alternatives such as synthetic artery-vein grafts. But many fistulas never mature enough to allow dialysis.

The multi-center trial included 877 people with total or partial kidney failure who underwent surgery to create a fistula. Half were given Plavix for six weeks after the surgery, while the other half were not.

Plavix did reduce the risk of blockage by 37 percent over the six-week period. Among the 866 people who were tested, 12.2 percent of those given Plavix had a blockage, compared to 19.5 percent of those not given the anti-clotting drug.

But Plavix therapy did not reduce the incidence of cases in which the fistula could not be used for dialysis, which was 61.8 percent in those getting the drug and 59.5 percent in those getting a placebo.

The rate of fistula failure was about 50 percent higher than anticipated, Dember said, and that might have an effect on future practice.

"There has been an increased emphasis on trying to create fistulas in as many patients as possible," she said. "So, the criteria have changed. We need to develop better methods for selecting suitable candidates for fistula creation."

The trial also indicated the direction that that research should take, Dember said.

"Our future efforts should be directed at understanding the basic mechanisms of fistula maturation," she said. "If we better understand those mechanisms, we should be able to identify maturity-enhancing interventions."

More information

The basics of kidney dialysis are explained by the U.S. National Library of Medicine.



SOURCES: Laura M. Dember, M.D., associate professor of medicine, Boston University School of Medicine; May 14, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Mix-Up Behind FDAs Failure to Inspect China Blood-Thinner Plant
2. Blood-Thinner Contaminant Traced to Chinese Plant
3. Clinical trials present better alternatives for dialysis patients
4. Nighttime Home Dialysis a Boon for Kidney Patients
5. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
6. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
7. New peritoneal dialysis diagnostic discovered
8. Early intervention dramatically improves outcomes for new dialysis patients
9. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
10. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
11. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... Chief Executive Officer of the medical device company, effective immediately. , “This is ... “Kevin has a strong track record in medical device market development and ...
(Date:1/15/2017)... ... , ... Whole Health Supply, LLC is announcing the release of an updated version of their ... , The 2017 edition has wide jaws that will accommodate nails up to 4mm ... as diabetics. This handle is reinforced for extra strength when pressing down on dense nails ...
(Date:1/15/2017)... ... , ... Wondering where to go this Valentine's Day? Well, there is a ... romantic, lobster feast in the comfort of your own home. Lobster Gram is introducing ... be featured until February 15th, 2017. , Romantic Dinner one is Lobster Gram's ...
(Date:1/14/2017)... ... January 13, 2017 , ... ... Soul, incorporating a magnesium-rich Mediterranean diet may lower the risk of type 2 ... notes that the many health and wellness benefits linked to a Mediterranean diet ...
(Date:1/13/2017)... ... ... The 18th European Congress: Perspectives in Lung Cancer will be held in Madrid ... expertly designed to meet the educational needs of European oncology clinicians and researchers who ... Giorgio V. Scagliotti, Professor of Oncology at the University of Torino, and organized by ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... LOVELAND, Colo. , Jan. 16, 2017  Northern ... , is bringing advanced laser treatments to ... specialty clinic focuses solely on the removal of unwanted ... and fading for tattoo cover-ups. "Tattoos are ... out the way we hope they would," said ...
(Date:1/16/2017)... January 16, 2017 ... Product Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl ... Beverages, Surface Coatings & Paints), Region - ... the market was valued at USD 4.51 ... reach USD 6.41 Billion by 2021, at ...
(Date:1/16/2017)... -- Transparency Market Research states that the leading ... a huge share of 43% in 2015. Apple Inc., F.Hoffmann-La ... overall market, grabbing the undivided attention of buyers with their ... strong product portfolio is expected to keep these companies in ... ...
Breaking Medicine Technology: